Drugmaker Eli Lilly (NYSE: LLY) hasn't been exempt from the recent market pullback, but its stock shot higher following the ...

Eli Lilly gains ground with Orforglipron’s success, showing growth potential and risks from momentum and tariffs. Read why ...

Last week, the markets wrapped up a shortened trading week (due to Good Friday) with widespread losses, as investors grappled with trade ...

Over the last couple of years, one of the best pharma stocks to own has been Eli Lilly ( LLY 14.56%). But now, an investment ...

We recently published a list of 10 Best Low Volatility Stocks to Buy Now. In this article, we are going to take a look at ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly & Co.'s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

With a market cap of $717 billion, Eli Lilly (LLY) is one of the world’s largest pharmaceutical companies. Lilly is ...

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

Eli Lilly announced the results of a clinical trial for its new pill, which the company said causes nearly 8% weight loss at certain dosages.

Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...